Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
In a 2-year trial, acute pancreatitis was reported in 8 semaglutide-treated patients (0.27 cases per 100 patient-years) and 10 placebo-treated patients (0.33 cases per 100 patient-years), both on a background of standard of care.1 In trials of patients receiving oral semaglutide, pancreatitis was reported as a serious adverse event in 6 patients (0.1 events per 100 patient-years) receiving semaglutide versus 1 in comparator-treated patients (less than 0.1 events per 100 patient-years)
Carefully designed trials assessing semaglutide-resmetirom combinations, integrated histologic, NIT, and molecular endpoints, could help define a new paradigm for multi-targeted metabolic and hepatic risk reduction in MASLD
Its about more than just a single medication
Informed Consent and Patient Safety in GLP-1 Medication Use: Navigating the Risks When prescribing GLP-1 medications, which are known to potentially induce gastroparesis, informed consent becomes crucial
